Petrelintide
Amylin analog · Roche
Headline dose
D3 of 5 (deepest cohort; mg blinded)
Weight loss
-10.7%
at week 42 · efficacy
AE discontinuation
4.5%
Status
phase 2
Weight loss trajectory #
Pivotal trial #
- Trial
- ZUPREME-1
- Indication
- obesity (no T2D)
- Duration
- 42 weeks
- ClinicalTrials.gov
- NCT06662539
- Sponsor
- Roche
Notes #
Phase 2 data; Phase 3 initiating H2 2026 -> $700M Zealand milestone. Placebo-like tolerability: any-AE-led discontinuation 4.5% vs 4.9% placebo (deck p36; total all-cause disc 15.5% vs 24.7% placebo). Nausea 19.6% vs 6.2% is the only GI AE clearly above placebo; vomiting LOWER than placebo (3.0% vs 6.2%). Non-GI signals: alopecia 4.7% pooled (up to 10.1% in one dose), vitamin D deficiency 6.9%. Best dose was the mid cohort (D3 -10.7%), not the top dose. Roche/Zealand 50/50.